Last reviewed · How we verify
Continue NA treatment
Continue NA treatment is a Unknown Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved.
The University Health Network in Toronto is continuing the treatment with a drug that does not have an FDA label. The drug's mechanism of action and specific details about its development and use are not provided. It appears to be in a research or investigational phase, with no clear indication of approved uses, safety profile, or commercial information. The lack of an FDA label suggests it may be used off-label or in clinical trials. Further details on the drug's mechanism, indications, safety, and commercial aspects are required for a comprehensive analysis.
At a glance
| Generic name | Continue NA treatment |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma (PHASE1)
- Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) (PHASE3)
- Salt-Sensitivity and Immunity Cell Activation (PHASE1, PHASE2)
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE2)
- Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection (PHASE1, PHASE2)
- Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC (EARLY_PHASE1)
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (PHASE2)
- A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continue NA treatment CI brief — competitive landscape report
- Continue NA treatment updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Continue NA treatment
What is Continue NA treatment?
Who makes Continue NA treatment?
What drug class is Continue NA treatment in?
What development phase is Continue NA treatment in?
What does Continue NA treatment target?
Related
- Drug class: All Unknown drugs
- Target: All drugs targeting Unknown
- Manufacturer: University Health Network, Toronto — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing